|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5348878A
(en)
|
1990-05-10 |
1994-09-20 |
Dana-Farber Cancer Institute |
Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
PT1053325E
(pt)
|
1998-02-05 |
2006-05-31 |
Glaxosmithkline Biolog Sa |
Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
|
|
AU3295299A
(en)
|
1998-02-19 |
1999-09-06 |
Xcyte Therapies, Inc. |
Compositions and methods for regulating lymphocyte activation
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
DE60014076T2
(de)
|
1999-04-19 |
2005-10-13 |
Glaxosmithkline Biologicals S.A. |
Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7514537B2
(en)
*
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
FR2827302B1
(fr)
|
2001-07-13 |
2003-10-10 |
Genoway |
Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
WO2004083244A2
(en)
|
2003-03-19 |
2004-09-30 |
Isogenis, Inc. |
Specific inhibition of allograft rejection
|
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
US7714119B2
(en)
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
|
EP1778296B1
(en)
|
2004-07-20 |
2012-06-06 |
Isogenis, Inc. |
Specific inhibition of autoimmunity and diseases associated with autoantigens
|
|
WO2006023598A2
(en)
*
|
2004-08-19 |
2006-03-02 |
University Of Maryland, Baltimore |
Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
|
|
AU2010225456B2
(en)
|
2009-03-18 |
2016-03-17 |
Carina Biotech Pty Ltd |
Biomarkers and uses thereof
|
|
EP2601521B1
(en)
|
2010-08-06 |
2018-05-02 |
Ludwig-Maximilians-Universität München |
Identification of t cell target antigens
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
WO2014090985A1
(en)
|
2012-12-13 |
2014-06-19 |
Universität Leipzig |
T-cell modulation by exon skipping
|
|
PT2956476T
(pt)
*
|
2013-02-18 |
2020-02-21 |
Vegenics Pty Ltd |
Moléculas de ligação e usos destas
|
|
KR102714111B1
(ko)
*
|
2013-02-20 |
2024-10-11 |
리제너론 파아마슈티컬스, 인크. |
사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
|
|
AU2015342867B2
(en)
|
2014-11-06 |
2020-03-26 |
University Of Maryland, Baltimore |
CD8alpha and T cell receptor variants and methods of using same in modulating immune cell responses
|
|
AU2015357526B2
(en)
*
|
2014-12-05 |
2022-03-17 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
|
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
MX2018005274A
(es)
|
2015-10-30 |
2019-09-19 |
The Regents Of The Universtiy Of California |
Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
|
|
WO2017100428A1
(en)
|
2015-12-09 |
2017-06-15 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of using same
|
|
US11661455B2
(en)
|
2016-02-05 |
2023-05-30 |
Orionis Biosciences BV |
Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
|
|
US11001631B2
(en)
*
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
CA3035075A1
(en)
|
2016-09-23 |
2018-03-29 |
Fred Hutchinson Cancer Research Center |
Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
|
|
AU2018226884B2
(en)
|
2017-03-03 |
2024-11-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
MX2019010972A
(es)
|
2017-03-15 |
2019-12-02 |
Hutchinson Fred Cancer Res |
Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
|
|
WO2019028295A1
(en)
*
|
2017-08-02 |
2019-02-07 |
La Jolla Institute For Allergy And Immunology |
COMPOSITIONS AND METHODS FOR ISOLATING AND / OR GENERATING SUB-ASSEMBLIES OF SPECIFIC CD4 + AND CD8 + T LYMPHOCYTES
|
|
MX2020011023A
(es)
|
2018-04-19 |
2021-01-29 |
Baylor College Medicine |
Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1.
|
|
CN113166778A
(zh)
|
2018-09-05 |
2021-07-23 |
葛兰素史克知识产权开发有限公司 |
T细胞修饰
|
|
GB201819540D0
(en)
|
2018-11-30 |
2019-01-16 |
Adaptimmune Ltd |
T cell modification
|